We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
- Authors
Shikina, Atsushi; Shinto, Eiji; Hashiguchi, Yojiro; Ueno, Hideki; Naito, Yoshihisa; Okamoto, Koichi; Kubo, Toru; Fukazawa, Satomi; Yamamoto, Junji; Hase, Kazuo
- Abstract
CD133 has been recently identified as a marker of putative cancer stem cells in colorectal tumors. The ability of cancer stem cells to resist chemotherapy was clinically highlighted; however, whether CD133 expression can predict chemoresistance remains controversial. The objective of the study was to determine the relationship between clinical benefits of adjuvant chemotherapy and CD133 expression status in colorectal cancer.
- Publication
Japanese journal of clinical oncology, 2014, Vol 44, Issue 1, p42
- ISSN
1465-3621
- Publication type
Journal Article
- DOI
10.1093/jjco/hyt168